Skip to main content
Evidence Snapshot

Prostaglandin D2 receptor

CHEMBL4427 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4427
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prostaglandin D2 receptor as ChEMBL target CHEMBL4427, mapped to UniProt Q13258. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prostaglandin D2 receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4427
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13258
Prostaglandin D2 receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Prostaglandin D2 receptor matters

As of 2026-09-13

Prostaglandin D2 receptor is reviewed as Prostaglandin D2 receptor (UniProt Q13258); Prostaglandin D2 receptor shows late clinical disease relevance led by Combined hyperlipidemia. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 9 approved drugs, 1022 compounds, and 131 assays, with lead potency reaching pChEMBL 10.7.

Disease context
Combined hyperlipidemia

Prostaglandin D2 receptor shows late clinical disease relevance led by Combined hyperlipidemia. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include LAROPIPRANT.

Start review with Combined hyperlipidemia because it currently carries late clinical support. Linked drugs include LAROPIPRANT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 9 approved drugs, 1022 compounds, and 131 assays for this target. The dominant activity type is IC50. CHEMBL1644207 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL1644207 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
9 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Prostaglandin D2 receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13258, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Combined hyperlipidemia is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1022
Total Compounds
131
Total Assays
9
Approved Drugs
IC50: 647.0, KI: 343.0, EC50: 185.0, KD: 1.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1644207
 10.7 IC50 —
No preferred name
CHEMBL426559
 10.5 Kd Approved
No preferred name
CHEMBL1644214
 10.3 IC50 —
No preferred name
CHEMBL426559
 10.1 IC50 Approved
No preferred name
CHEMBL1644206
 10.0 IC50 —

Approved Drugs

Structure Compound First Approval
SELEXIPAG
CHEMBL238804
 2015
ILOPROST
CHEMBL494
 2003
TREPROSTINIL
CHEMBL1237119
 2002
LAROPIPRANT
CHEMBL426559
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:30:29Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4427